Relative Bioavailability of the Baricitinib (LY3009104) Commercial Tablet Compared to the Phase 2 Tablets and the Effect of Food on the Bioavailability of the Commercial Tablet in Healthy Japanese Subjects

Trial Profile

Relative Bioavailability of the Baricitinib (LY3009104) Commercial Tablet Compared to the Phase 2 Tablets and the Effect of Food on the Bioavailability of the Commercial Tablet in Healthy Japanese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Diabetic nephropathies; Psoriasis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Nov 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 27 Oct 2014 Planned initiation date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
    • 17 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top